Funding for this research was provided by:
European Regional Development Fund through the Interreg Deutschland-Danmark program (087-1.1-18, 087-1.1-18, 087-1.1-18, 087-1.1-18, 087-1.1-18)
Universität zu Lübeck
Received: 2 May 2022
Accepted: 2 September 2022
First Online: 17 September 2022
: The trial was approved by the responsible ethics committees in Lübeck, Hannover and Barakaldo (initial approval by the ethics committee at the University of Lübeck, reference number 19–302). It was conducted in accordance with the principles laid out in the Declaration of Helsinki and the principles of Good Clinical Practice (ICH-GCP E6). Patients were included after having given written informed consent.
: Not applicable.
: Dirk Rades and Stefan Janssen belong to the editorial board of BMC Cancer; otherwise, they have no competing interest related to this trial. Other authors declare no competing interest.